Metabolic Capacity of Israeli Populations
Information source: Hadassah Medical Organization
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Healthy Volunteers
Intervention: Debrisoquine (Drug); Mephenytoin (Drug); Dapsone (Drug); Caffeine (Drug)
Phase: N/A
Status: Terminated
Sponsored by: Hadassah Medical Organization Official(s) and/or principal investigator(s):
Yoseph Caraco, MD, Principal Investigator, Affiliation: Hadassah Medical Organization
Summary
The ability to metabolize drugs varies greatly among individuals. Major fraction of this
variability lies in genetic polymorphisms of genes encoding for enzymes responsible for both
phase I and phase II reactions.
The purpose of this study ws to evaluate the phenotypic activity and the frequency of genetic
polymorphisms in different phase II and phase I enzymes among various populations residing in
Israel.
Clinical Details
Official title: Phenotypic and Genotypic Evaluation of Cytochrome P450 Isoforms in Populations of Different Ethnic Composition
Study design: Other, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment
Primary outcome: Phenotypic measurements of various P450 and non-P450 enzymes involved in drug metabolism.Frequency of genetic polymorphisms in these enzymes among different Israeli populations.
Eligibility
Minimum age: 20 Years.
Maximum age: 50 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Age range 20-50
- Absence of significant disease state
Exclusion Criteria:
- The presence of significant disease states
- The regular use of drugs (including birth control pills)
Locations and Contacts
Hadassah Medical Organization, Jerusalem, Israel
Additional Information
Starting date: July 1995
Last updated: March 17, 2008
|
